NEW ORLEANS, Oct. 11, 2022 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Get Help
Abbott investors should visit us at https://claimsfiler.com/cases/nyse-abt-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Abbott and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 17, 2022, the U.S. Food and Drug Administration (“FDA”) announced that its inspection of the Company’s Sturgis, Michigan facility, prompted by consumer complaints of infant illness, had yielded several positive contamination results for the Cronobacter sakazakii bacteria, linked to infant illnesses and death. On the same day, the Company, without mention of the FDA investigation, recalled certain infant formula products, including the popular brands Similac, Alimentum and EleCare, all manufactured in Sturgis. On this news, shares of Abbott declined by $3.79 per share, or 3.14%.
Then, on March 22, 2022, the FDA reported that, although not “final FDA determinations,” its most recent inspection conducted between January 31, 2022 and March 18, 2022 revealed that the Company failed to establish process controls “designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment” and failed to “ensure that all surfaces that contacted infant formula were maintained to protect infant formula from being contaminated by any source.” On this news, shares of Abbott declined by an additional $4.97 per share, or 4%.
Finally, on June 8, 2022, it was reported that a whistleblower complaint identifying numerous serious examples of misconduct at Sturgis related to the above had been filed with the U.S. Occupational Safety & Health Administration (“OSHA”) in February 2021, and that OSHA had delivered that complaint to Abbott Laboratories and the FDA during the same month. On this news, shares of Abbott declined by an additional 3.5%, further damaging investors.
The case is Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No. 22-cv-04661.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
- Liquid Polybutadiene Market Size Expected to Hit US$ 642.7 million by 2033, With 6.1% CAGR: Fact.MR Study - March 23, 2023
- Acronis enhances security offerings with Intel® TDT technology - March 23, 2023
- Soldier System Market is estimated to reach revenue of US$ 17.0 billion by 2031; The body armor segment holds 27.5% of market share. - March 23, 2023
